Denali Therapeutics director Nancy Thornberry sold 11,439 shares in two transactions priced from $22.85 to $23.74 per share on 2026-09-02. She retained 19,686 Denali Therapeutics shares afterward, giving investors the director’s reported remaining ownership following the transactions.

Key Highlights

  • The transactions took place on 2 September 2026 and both carried SEC transaction code S.
  • Nancy Thornberry’s reported ownership stood at 19,686 Denali Therapeutics shares after the sales.
  • The 11,439-share total was divided across two separate transactions.

Denali Therapeutics Inc. (NASDAQ: DNLI) director Nancy Thornberry sold 11,439 shares at prices ranging from $22.85 to $23.74 per share. The reported transactions leave Thornberry with 19,686 shares of Denali Therapeutics.

Two Transactions Recorded on 2 September 2026

The sales occurred on 2 September 2026 and were recorded as two separate transactions. Both entries used SEC transaction code S. Thornberry is identified as a director of Denali Therapeutics. The post-transaction ownership figure was 19,686 shares.